Objectives: The Generic Reference Price (GRP) was introduced in Italy in 2001. The main purpose of this paper is: (a) produce evidence regarding the effect of GRP on prices; (b) test the hypothesis that there is a reallocation of demand from the genericated (and reference-priced) molecules to patent-protected products that have the same therapeutic indication. Methods: The analysis used a unique dataset of quantities and revenues of six therapeutic groups that were observed for more than a decade. Difference-in-Differences analysis is applied. Results: On average, prices dropped 13% more in groups to which GRP was applied than in other groups. Moreover, each entry was associated with a price drop of around 2.8%. On the other hand, GRP did not induce any significant switching towards in-patent molecules. Conclusions: Results provide the first empirical results of the impact of GRP on prices in Italy and evidence that GRP cannot be held solely responsible for the often reported demand reallocation towards new and in-patent molecules.

The impact of generic reference pricing in Italy, a decade on

GHISLANDI, SIMONE;ARMENI, PATRIZIO;JOMMI, CLAUDIO
2013-01-01

Abstract

Objectives: The Generic Reference Price (GRP) was introduced in Italy in 2001. The main purpose of this paper is: (a) produce evidence regarding the effect of GRP on prices; (b) test the hypothesis that there is a reallocation of demand from the genericated (and reference-priced) molecules to patent-protected products that have the same therapeutic indication. Methods: The analysis used a unique dataset of quantities and revenues of six therapeutic groups that were observed for more than a decade. Difference-in-Differences analysis is applied. Results: On average, prices dropped 13% more in groups to which GRP was applied than in other groups. Moreover, each entry was associated with a price drop of around 2.8%. On the other hand, GRP did not induce any significant switching towards in-patent molecules. Conclusions: Results provide the first empirical results of the impact of GRP on prices in Italy and evidence that GRP cannot be held solely responsible for the often reported demand reallocation towards new and in-patent molecules.
2012
Ghislandi, Simone; Armeni, Patrizio; Jommi, Claudio
File in questo prodotto:
File Dimensione Formato  
EJHE2012_accettazione.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 35.25 kB
Formato Adobe PDF
35.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
EJHE2013.pdf

non disponibili

Tipologia: Pdf editoriale (Publisher's layout)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 335.58 kB
Formato Adobe PDF
335.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11565/3774347
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 8
social impact